Tome Biosciences
PrivateLast Round
Series B
Dec 12, 2023
Total Funding Raised
$213M
Company Overview
Tome Biosciences is a biotechnology company that provides programmable gene insertion technology to enable precise genetic modifications for the detection and elimination of harmful DNA during infections, facilitating patient cures through advanced cell and genome engineering.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tome Biosciences Comps
Public and private peers based on sector, stage, and business model.
Tome Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 12, 2023 |
Tome Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series B |
| GV | Series B |
| ARCH Venture Partners | Series B |
| Alexandria Venture Investments | Series B |
| Longwood Fund | Series B |
| Polaris Partners | Series B |
| Fujifilm Corporation | Series B |
Tome Biosciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Tome Biosciences's valuation, stock price, and market status.
